Caroline M. Tanner

Caroline M. Tanner's AcademicInfluence.com Rankings

Caroline M. Tanner

Medical

#2020

World Rank

#2411

Historical Rank

Neurology

#197

World Rank

#270

Historical Rank

medical Degrees

Download Badge

Medical

Caroline M. Tanner's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Caroline M. Tanner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Caroline M. Tanner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Parkinson disease (2017) (1821)
Levodopa and the progression of Parkinson's disease. (2004) (1676)
Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. (2003) (1586)
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. (1993) (1186)
Variable expression of Parkinson's disease (1990) (1167)
The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
Rotenone, Paraquat, and Parkinson’s Disease (2011) (1123)
Parkinson disease in twins: an etiologic study. (1999) (936)
Effect of deprenyl on the progression of disability in early Parkinson's disease. (1989) (886)
Frequency of bowel movements and the future risk of Parkinson’s disease (2001) (760)
Association of coffee and caffeine intake with the risk of Parkinson disease. (2000) (720)
Association of olfactory dysfunction with risk for future Parkinson's disease (2008) (669)
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. (2002) (547)
Prevalence of Parkinson’s disease across North America (2018) (537)
Lewy bodies and parkinsonism in families with parkin mutations (2001) (488)
Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease (2011) (482)
Excessive daytime sleepiness and subsequent development of Parkinson disease (2005) (403)
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa (1996) (356)
DLB and PDD boundary issues (2007) (351)
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. (2013) (342)
Freezing of gait in PD (2001) (328)
Urate as a predictor of the rate of clinical decline in Parkinson disease. (2009) (324)
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. (2020) (295)
The role of environmental toxins in the etiology of Parkinson's disease (1989) (285)
Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2 (2012) (274)
Head injury and Parkinson's disease risk in twins (2006) (264)
Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial (2002) (251)
Mutations in COQ2 in familial and sporadic multiple-system atrophy. (2013) (246)
Epidemiology of Parkinson’s Disease (1992) (243)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
Parkinsonian signs and substantia nigra neuron density in decendents elders without PD (2004) (228)
Do environmental toxins cause Parkinson's disease? A critical review (1990) (226)
Occupation and risk of parkinsonism: a multicenter case-control study. (2009) (225)
Cognitive performance of GBA mutation carriers with early-onset PD (2012) (225)
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease (2006) (224)
Polysomnographic sleep measures in Parkinson's disease patients with treatment‐induced hallucinations (1993) (214)
Freezing of gait in PD: Prospective assessment in the DATATOP cohort (2001) (211)
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor (2001) (205)
Environmental Factors in the Etiology of Parkinson's Disease (1987) (204)
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease (2007) (204)
Bowel movement frequency in late‐life and incidental Lewy bodies (2007) (202)
Traumatic brain injury in later life increases risk for Parkinson disease (2015) (200)
Epidemiology of Parkinson’s Disease (1992) (195)
Pain in Parkinson's disease (1986) (193)
Plantation work and risk of Parkinson disease in a population-based longitudinal study. (2002) (191)
Association of olfactory dysfunction with incidental Lewy bodies (2006) (190)
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease (1997) (187)
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. (2015) (178)
Smoking and Parkinson’s disease in twins (2002) (172)
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study (2016) (169)
Clonidine and Gilles de la Tourette's syndrome: Double‐blind study using objective rating methods (1987) (162)
Midlife adiposity and the future risk of Parkinson’s disease (2002) (153)
Early dopaminergic drug-induced hallucinations in parkinsonian patients (1998) (152)
Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation. (2005) (146)
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases (2019) (146)
Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial (2008) (144)
Current and projected future economic burden of Parkinson’s disease in the U.S. (2020) (144)
Environmental risk factors in Parkinson's disease (1990) (143)
Epidemiology of Parkinson's disease and akinetic syndromes (2000) (143)
Research priorities in spasmodic dysphonia (2008) (142)
The past, present, and future of telemedicine for Parkinson's disease (2014) (142)
Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. (2012) (141)
National randomized controlled trial of virtual house calls for Parkinson disease (2017) (140)
Solvent exposures and parkinson disease risk in twins (2012) (139)
Bupropion in Parkinson's disease (1984) (138)
Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. (2003) (136)
Consumption of milk and calcium in midlife and the future risk of Parkinson disease (2005) (135)
Environmental factors and Parkinson's disease (1989) (133)
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial (2017) (132)
Autonomic dysfunction in Parkinson's disease (1986) (132)
Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) (2015) (131)
Natural History of Multiple System Atrophy in North America: A Prospective Cohort Study (2015) (129)
How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort? (2016) (128)
An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease (2001) (127)
Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials (2017) (127)
Epidemiologic aspects. (2000) (127)
Botulinum toxin injection for spasmodic torticollis (1992) (124)
Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3) (2017) (123)
Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease (2005) (123)
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. (2010) (123)
Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts (2017) (122)
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort (2018) (113)
Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease (2012) (110)
Measurement and Analysis (2004) (109)
Clinical features in early Parkinson disease and survival. (2009) (108)
Health related quality of life in early Parkinson's disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. (2009) (107)
Dietary fat intake, pesticide use, and Parkinson's disease. (2014) (106)
Nicotine and Parkinson's disease: Implications for therapy (2008) (104)
Benefits and Risks of Pharmacological Treatments for Essential Tremor (2003) (99)
Variants associated with Gaucher disease in multiple system atrophy (2015) (97)
Epidemiology of movement disorders (1994) (97)
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study (2006) (96)
Essential tremor in twins (2001) (95)
Nongenetic causes of Parkinson's disease. (2006) (94)
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease (2020) (94)
Failure to find the a‐synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease (1998) (94)
Survival in Parkinson disease (2005) (93)
Occupation and parkinsonism in three movement disorders clinics (2005) (90)
The best medicine? The influence of physical activity and inactivity on Parkinson's disease (2016) (89)
A rating scale for Gilles de la Tourette's syndrome (1987) (87)
Dysphagia after botulinum toxin injections for spasmodic torticollis (1992) (86)
Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease (2010) (85)
Risk factors for progression in Parkinson's disease (1988) (85)
Head injury, alpha‐synuclein Rep1, and Parkinson's disease (2012) (83)
Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort (2017) (81)
Absence of mutations in the coding region of the α-synuclein gene in pathologically proven Parkinson's disease (1998) (81)
Advances in environmental epidemiology (2010) (80)
The North American Multiple System Atrophy Study Group (2005) (80)
Genetic modification of the association of paraquat and Parkinson's disease (2012) (79)
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. (2010) (78)
Optimizing the ongoing search for new treatments for Parkinson disease (2006) (77)
The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk (2014) (77)
Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease (2019) (76)
Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease. (2015) (76)
Research on the Premotor Symptoms of Parkinson’s Disease: Clinical and Etiological Implications (2013) (76)
Does a long preclinical period occur in Parkinson's disease? (1991) (76)
Mendelian randomization of serum urate and parkinson disease progression (2014) (76)
Which dyskinesia scale best detects treatment response? (2013) (75)
Dietary intake in adults at risk for Huntington disease (2009) (74)
Epidemiology of Tourette syndrome. (1997) (74)
Bowel movement frequency in late‐life and substantia nigra neuron density at death (2009) (73)
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression (2020) (73)
Smell identification ability in twin pairs discordant for Parkinson's disease (2005) (72)
Chronic agonist therapy for Parkinson's disease (1985) (71)
A responsive outcome for Parkinson's disease neuroprotection futility studies (2005) (71)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
Teaching program for the movement disorder society‐sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS‐UPDRS) (2010) (67)
Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007 (2008) (67)
Verification of self-report of zygosity determined via DNA testing in a subset of the NAS-NRC twin registry 40 years later. (2005) (65)
Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study (2015) (64)
A High-Density Genome-Wide Association Screen of Sporadic ALS in US Veterans (2012) (61)
The epidemiology of tics and Tourette syndrome in children and adolescents. (2001) (61)
Caffeine consumption and risk of dyskinesia in CALM‐PD (2013) (59)
Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. (2012) (59)
Potential outcome measures and trial design issues for multiple system atrophy (2007) (58)
Occupational and environmental causes of parkinsonism. (1992) (57)
Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California. (2015) (57)
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. (2009) (56)
Minimum incidence of primary cervical dystonia in a multiethnic health care population (2007) (55)
Reproducibility of data-driven Parkinson's disease subtypes for clinical research. (2018) (54)
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
Lessons Learned From Past Gene-Environment Interaction Successes (2017) (54)
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease (2010) (53)
Epidemiology of Parkinson's disease (2007) (51)
A longitudinal program for biomarker development in Parkinson's disease: A feasibility study (2009) (50)
Olfaction in Parkin heterozygotes and compound heterozygotes (2010) (49)
Neuroepidemiology: From Principles to Practice (2003) (48)
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits (2015) (48)
Peptidoglycan recognition protein genes and risk of Parkinson's disease (2014) (47)
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. (2016) (47)
L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. (1990) (46)
Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. (2014) (46)
Current and projected future economic burden of Parkinson’s disease in the U.S. (2020) (45)
Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance (2020) (45)
Trial of Cinpanemab in Early Parkinson's Disease. (2022) (45)
Pergolide mesylate and idiopathic Parkinson disease (1982) (45)
Concordance for Parkinson's disease in twins: A 20‐year update (2019) (45)
Comorbid cancer in Parkinson's disease (2010) (45)
Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease (2019) (43)
CYP2D6 allelic frequencies in young-onset Parkinson's disease (1996) (43)
A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson’s disease (2019) (41)
Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments (2013) (41)
Cholinergic mechanisms in Tourette syndrome (1982) (41)
Knowledge gaps and research recommendations for essential tremor. (2016) (41)
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study (2017) (40)
Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. (2013) (40)
Familial aggregation of Parkinson's disease in a multiethnic community‐based case‐control study (2010) (39)
Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson’s Disease Using Screening of Multiple Prospective New Treatments (2013) (39)
Progression of Parkinson's disease without levodopa (1987) (39)
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study (2020) (38)
Midlife milk consumption and substantia nigra neuron density at death (2016) (37)
Opsoclonic cerebellopathy: A paraneoplastic syndrome responsive to thiamine. (1981) (37)
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease (2020) (36)
The relation between depression and parkin genotype: the CORE-PD study. (2011) (36)
β-adrenoreceptors and the risk of Parkinson's disease (2020) (35)
Primary writing tremor (1982) (35)
A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group. (1994) (35)
G2019S mutation in the leucine‐rich repeat kinase 2 gene is not associated with multiple system atrophy (2007) (34)
Remote smartphone monitoring of Parkinson’s disease and individual response to therapy (2021) (33)
The electroencephalogram in Tourette syndrome (1982) (32)
The Impact of COVID‐19 on Access to Parkinson's Disease Medication (2020) (30)
Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation (2003) (29)
Impact of Alzheimer's-type dementia and information source on the assessment of depression (1995) (29)
Late-life hemoglobin and the incidence of Parkinson's disease (2012) (29)
Pramipexole in Levodopa-treated Parkinson Disease Patients of African, Asian, and Hispanic Heritage (2007) (29)
Non-linearity of Parkinson’s disease progression: implications for sample size calculations in clinical trials (2005) (28)
Adrenal medullary autografts in patients with Parkinson's disease. (1989) (28)
Effect of Reproductive Factors and Postmenopausal Hormone Use on the Risk of Amyotrophic Lateral Sclerosis (2006) (27)
Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder (2020) (27)
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study (2010) (25)
Parkinson's disease research in a prospective cohort in China. (2015) (25)
USE OF ANTIHYPERTENSIVES AND THE RISK OF PARKINSON DISEASE (2009) (25)
Reliability and validity of two self-administered questionnaires for screening restless legs syndrome in population-based studies. (2010) (25)
Effect of non‐steroidal anti‐inflammatory medications on the risk of amyotrophic lateral sclerosis (2007) (25)
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease (2010) (24)
Epidemiology of Parkinson’s Disease: An Overview (2004) (24)
Meige disease (1982) (24)
Latah in Jakarta, Indonesia (2001) (24)
Association of moderate polyglutamine tract expansions in the slow calcium-activated potassium channel type 3 with ataxia. (2001) (23)
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine (2015) (23)
Telemedicine Use for Movement Disorders: A Global Survey. (2018) (23)
Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. (1989) (23)
Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. (1998) (23)
Cervical Dystonia Incidence and Diagnostic Delay in a Multiethnic Population (2019) (22)
Weekly drug holiday in Parkinson disease (1981) (22)
Pergolide in Parkinson's disease. (1983) (22)
Dopamine agonists in early therapy for Parkinson disease: promise and problems. (2000) (22)
Abnormal liver enzyme‐mediated metabolism in Parkinson's disease (1991) (21)
Selected health and lifestyle factors, cytosine‐adenine‐guanine status, and phenoconversion in Huntington's disease (2018) (21)
Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis. (1987) (21)
Parkinson's disease and motor-neuron disease in former prisoners-of-war (2000) (20)
A second honeymoon for Parkinson's disease? (2013) (19)
Early intervention in Parkinson's disease: epidemiologic considerations. (1996) (19)
Predictors of time to initiation of symptomatic therapy in early Parkinson's disease (2016) (19)
Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson’s Disease Research: The Fox Insight Cohort Experience (2020) (18)
Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts (2011) (18)
Caffeine, creatine, GRIN2A and Parkinson's disease progression (2017) (18)
Virtual visits for Parkinson disease: A multicenter noncontrolled cohort (2017) (18)
Pergolide mesylate (1985) (17)
The relationship between obsessive‐compulsive symptoms and PARKIN genotype: The CORE‐PD study (2015) (17)
Relationship of Aluminum to Neurocognitive Dysfunction in Chronic Dialysis Patients (1988) (17)
Seborrheic Dermatitis and Risk of Future Parkinson's Disease (PD) (S42.001) (2012) (16)
Selegiline and Parkinson’s disease (2000) (16)
Predicting Parkinson's disease. Discussion (1990) (16)
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease (2021) (15)
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease (2020) (15)
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102 (2018) (14)
EPIDEMIOLOGY OF PARKINSON'S DISEASE (1996) (14)
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. (2019) (14)
Excessive daytime sleepiness and topographic expansion of Lewy pathology (2019) (14)
A practical approach to remote longitudinal follow‐up of Parkinson's disease: The FOUND study (2014) (14)
Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. (1986) (14)
Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person (2020) (13)
Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice (2020) (13)
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP) (2020) (13)
Role of Neuroinflammation in Parkinson Disease: The Enigma Continues. (2016) (13)
Brain organochlorines and Lewy pathology: The Honolulu‐Asia aging study (2012) (13)
Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures (2019) (13)
Textbook of Clinical Neuropharmacology and Therapeutics (1992) (12)
Heart rate variability in leucine‐rich repeat kinase 2‐associated Parkinson's disease (2017) (12)
Verification of Self-Report of Zygosity Determined via DNA Testing in a Subset of the NAS-NRC Twin Registry 40 Years Later (2005) (12)
1.003 FACILITATING CLINICAL RESEARCH: THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS (NINDS) AND STROKE PARKINSON'S DISEASE COMMON DATA ELEMENTS PROJECT (2012) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
Remote telemedicine evaluation of deep brain stimulation candidacy: Retrospective cohort analysis. (2020) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
The autonomic nervous system in Gilles de la Tourette's syndrome (1987) (12)
Video-based Parkinson’s disease assessments in a nationwide cohort of Fox Insight participants (2021) (12)
Ideational fluency in Parkinson's disease (1992) (11)
When brawn benefits brain: physical activity and Parkinson's disease risk. (2015) (10)
PD or not PD? (2003) (10)
A Bayesian mathematical model of motor and cognitive outcomes in Parkinson’s disease (2017) (10)
Structural variants in the vesicular monoamine transporter do not contribute to sporadic Parkinson's disease (2006) (10)
Electrocardiographic changes predate Parkinson’s disease onset (2020) (9)
Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD) (2020) (9)
Exploring the clinical burden of OFF periods in Parkinson disease. (2020) (9)
Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology (2018) (9)
Current Knowledge on the Evolution of Care Partner Burden, Needs, and Coping in Parkinson's Disease (2021) (9)
Aluminum neurotoxicity: a reevaluation. (1991) (9)
Gilles de la tourette's syndrome in twins: Clinical and neurochemical data (1990) (9)
Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia (2021) (8)
Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants (2014) (8)
Movement disorder society symposium on cortical‐asal ganglionic degeneration (CBGD) and its relationship to other asymmetrical cortical degeneration syndromes (ACDs) washington, D. C. October 25–26, 1995 (1996) (8)
Marinesco bodies and substantia nigra neuron density in Parkinson's disease (2017) (8)
Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease (2022) (7)
High-dosage vitamin E supplementation and all-cause mortality. (2005) (7)
Parkin gene variations and parkinsonism: Association does not imply causation (2007) (7)
Occupation and Risk of Parkinsonism (2016) (7)
A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson’s Disease: Study Protocol and Design (2020) (7)
Deprenyl for the treatment of early Parkinson's disease. (1990) (6)
The economic impact of OFF periods in Parkinson disease. (2020) (6)
Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study. (2021) (5)
Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind. (2017) (5)
Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson's disease (1994) (5)
Study Design, Measures of Effect, and Sources of Bias (2004) (5)
RE-KINECT (2020) (5)
P2.204 A randomized, double-blind, placebo-controlled, delayed start study to assess safty, tolerability and efflcacy of green tea polyphenols in Parkinson's disease (2009) (5)
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism (2021) (5)
The Microbiome in Neurodegenerative Disease (2018) (5)
AlzheimerÃ¢ÂÂs and ParkinsonÃ¢ÂÂs Diseases Face Common Challenges inTherapeutic Development: Role of the Precompetitive Consortium,Coalition Against Major Diseases (2015) (4)
Pharmacological Options for the Management of Dyskinesias (1996) (4)
Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease (2022) (4)
Problematic Mobile Gaming in Parkinson's Disease: An Impulse Control Disorder for the Smartphone (2017) (4)
Parkinson's Disease; Epidemiology (2014) (4)
The NAS-NRC Twin Registry and Duke Twins Study of Memory in Aging: An Update (2019) (4)
Recruitment for Remote Decentralized Studies in Parkinson’s Disease (2021) (4)
Cross-Sectional and Longitudinal Validation of Serum Neurofilament Light Chain (NfL) as a Biomarker of Parkinson’s Disease Progression (2019) (4)
Vitamin E and PD (1993) (4)
Path to Parkinson Disease Prevention (2022) (4)
Levodopa drug holiday versus drug dosage reduction in Parkinson's disease (1994) (4)
Rotenone and Parkinson's disease: reduced sensitivity in females. (2019) (4)
Tardive Dyskinesia: Prevention and Treatment (1986) (4)
Occupational exposures and parkinsonism among Shanghai women textile workers (2018) (3)
Epidemiology of dystonia (2007) (3)
Treatment of Tardive Dyskinesia: Other Therapies (1983) (3)
ADS-5102 provided reduction in motor complications in Parkinson’s disease patients with levodopa-induced dyskinesia switched from amantadine IR: Subgroup analysis from open-label study (ease LID 2) (2017) (3)
Safety and Efficacy Study of ADS-5102 (Amantadine HCl) Extended Release Capsules in Levodopa-Induced Dyskinesia (EASED Study) (P4.053) (2014) (3)
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease (2021) (3)
Neuroepidemiology: Fundamental Considerations (2004) (3)
Liver enzyme abnormalities in Parkinson's disease. (1991) (3)
A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson’s Disease (PD) Patients with Dyskinesia (P2.052) (2018) (3)
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease (2021) (3)
Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries. (2020) (3)
The Use of Dopamine Agonists and Antagonists in Neurology (1984) (2)
Progression of Parkinson's disease (1989) (2)
Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors (2022) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
Mendel and urate: Acid test or random noise? (2018) (2)
Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial (2022) (2)
Controlled‐release Sinemet (1987) (2)
Incidence of Primary Torsion Dystonia in a Multiethnic Population (S53.001) (2013) (1)
Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. (1988) (1)
Pesticide Exposure and Parkinsonʼs Disease (PD) in the Agricultural Health Study (AHS) (2009) (1)
Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based study (2021) (1)
Weekly drug holiday in PD (1982) (1)
Movement Disorders Induced by Neuroleptic Drugs (1986) (1)
S-108: Associations of Long-Term Average Ozone and PM2.5 Concentrations with Parkinsonʼs Disease among Participants in the Agricultural Health Study (2012) (1)
Pesticides and Risk for Parkinson Disease (2007) (1)
Trichloroethylene: An Invisible Cause of Parkinson’s Disease? (2023) (1)
Effects of ADS-5102 on non-motor symptoms (NMS) in Parkinson’s disease patients with dyskinesia (P1.039) (2018) (1)
Brain and Spinal Cord Injury (2004) (1)
Heart Rate Variability (HRV) from a 10-second Electrocardiogram (ECG) in Parkinson’s Disease (PD) and Control (P1.037) (2018) (1)
Disease Primers PARKINSON DISEASE (2017) (1)
Innovative Recruitment Strategies Increase Diversity of Participation in the Fox Insight Longitudinal Cohort (S16.009) (2019) (1)
117 RE-KINECT: Real-World Dyskinesia Screening Study and Registry in Patients Taking Antipsychotic Agents: Interim Baseline Burden of Illness Results (2018) (1)
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study (2023) (1)
Consensus Statement Parkinson’s Disease and the Environment Collaborative on Health and the Environment and Parkinson's Action Network (CHE PAN) Conference June 26–28, 2007 (2008) (1)
The epidemiology of cognitive function in Parkinson's disease. (2022) (1)
A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease (2022) (1)
Evidence-Based Medicine in Neurology (2004) (1)
Polychlorinated Biphenyls (PCBs) and Parkinson's Disease (PD): Effect Modification by Membrane Transporter Variants (S32.004) (2016) (1)
Prodromal Diagnoses in the Electronic Medical Record (EMR) Differ in Parkinson’s Disease (PD), Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), and Progressive Supranuclear Palsy (PSP) (P3.347) (2016) (1)
Parkinson's Disease: Genetic Epidemiology and Overview (2003) (1)
Temporary levodopa withdrawal. (1986) (1)
Parkinson's Disease Risk Is Associated with Variants in Genes That Bind Bacterial Cell-Wall Peptidoglycan (P05.051) (2013) (1)
PSYCHIATRIC REACTION TO ERGOT DERIVATIVES (1979) (1)
Reply to: Diagnostic Delay in Cervical Dystonia‐Dystonia With Antecedent ET? (2020) (1)
Surveying Global Availability of Parkinson's Disease Treatment. (2022) (1)
Early Clinical Predictors of Treatment‐Resistant and Functional Outcomes in Parkinson's Disease (2016) (1)
Heart Rate Variability in LRRK2 Parkinson’s Disease (S37.004) (2014) (1)
CPK values in Parkinson's disease. (1981) (0)
Alaska Native Parkinson's Disease Registry (2013) (0)
6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECT Study (2019) (0)
Manganese Content in Hair of Patients with Parkinson’s Disease: Manganese Deficiency and Susceptibility Towards Parkinson’s Disease (1990) (0)
Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". (2019) (0)
1.117 ENDOTOXIN AND RISK OF PARKINSONISM AMONG WOMEN TEXTILE WORKERS IN SHANGHAI, CHINA: STUDY DESIGN AND ENROLLMENT PROGRESS (2012) (0)
Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform (2021) (0)
Enhancing clinical information display to improve patient encounters: human-centered design and evaluation of the Parkinson’s Disease-BRIDGE platform (Preprint) (2021) (0)
RE-KINECT, A REAL-WORLD, PROSPECTIVE TARDIVE DYSKINESIA SCREENING STUDY: AN EVALUATION OF BASELINE CHARACTERISTICS IN OLDER PATIENTS (2019) (0)
Association of Coffee and Caffeine Consumption with Brain Lewy Pathology in the Honolulu-Asia Aging Study (S42.005) (2012) (0)
Prevalence of Parkinsonism and Parkinson Disease in Urban and Rural Populations from Latin America: A Community Population-Based Survey (2021) (0)
Estimating the Cumulative Risk of PD in Carriers of Parkin Mutations: The CORE-PD Study (PD4.007) (2012) (0)
0442 Occupational exposures and parkinsonism among women textile workers in shanghai, china (2017) (0)
VITAMIN E AND PD. AUTHORS' REPLY (1993) (0)
Health Services Research in Neurology (2004) (0)
Bad Air and Parkinson Disease-The Fog May Be Lifting. (2021) (0)
Pooled analysis of phase 3 studies of ADS-5102 for levodopa-induced dyskinesia: A detailed review of MDS-UPDRS, part IV (motor complications) (2018) (0)
Pharmacology of cranial dystonia (1983) (0)
Proposal for a Biologic Staging System of Parkinson's Disease. (2023) (0)
Relationship of Brain Organochlorine Levels with Lewy Pathology: The Honolulu-Asia Aging Study (2011) (0)
Assessing Morbidity and Mortality Associated with Pallidotomy (2002) (0)
Reply (2012) (0)
No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187) (2013) (0)
Clinical Trials in Neurology (2004) (0)
Title Electrocardiographic changes predate Parkinson ' s disease onset (2020) (0)
Polychlorinated Biphenyls, Organochlorines & PD Risk: A Case Control Study in Alaska (2006) (0)
Cervical dystonia (CD) incidence and diagnostic delay in a multiethnic health maintenance organization. (S36.004) (2015) (0)
Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson's disease (2023) (0)
Risk of Parkinson's Disease after Traumatic Brain Injury versus Nonbrain Trauma (S36.002) (2015) (0)
Blepharospasm in a Multiethnic Population (P3.348) (2016) (0)
Heart Rate Variability in leucine-rich repeat kinase 2Associated Parkinsons Disease (2017) (0)
The Effect of Parkin Mutation Status on Cognitive Functioning in EOPD Patients with Long Disease Duration: The CORE-PD Study (PD7.008) (2012) (0)
2.17.1 OCCUPATIONAL CHEMICAL EXPOSURES & RISK FOR PARKINSON'S DISEASE (2012) (0)
Parkinson Disease in Twins (2017) (0)
Risk of Parkinson's Disease (PD) Associated with the Herbicide Paraquat Is Attenuated by High Dietary Intake of Polyunsaturated Fatty Acids (PUFAs) (S42.004) (2012) (0)
Selected Health and Life Style Factors and Time to Phenoconversion in Huntington’s Disease (S47.003) (2014) (0)
TANNER, Caroline: California/USA (2019) (0)
The Parkinson's Registry Investigation of Diagnosis and Etiology (PRIDE) Study (2015) (0)
Polychlorinated Biphenyls, Organochlorines & PD Risk: A Case Control Study in Alaskan Natives (2011) (0)
Reply (1989) (0)
California's Parkinson's Disease Registry Pilot Project - Coordination Center and Northern California Ascertainment (2014) (0)
Paraquat Use Modifies the Association of Head Injury and Parkinson's Disease (PD) (S42.003) (2012) (0)
Predicting Parkinson’s Disease and Its Pathology via Simple Clinical Variables (2021) (0)
Parkinson's Disease, Epidemiology (2003) (0)
Training for Research on Aging and Chronic Disease (2017) (0)
Quality of life in Essential Tremor Questionnaire (2018) (0)
Protective Glove Use and Workplace Hygiene Practices Modify Associations between Pesticides and Parkinson's Disease (2014) (0)
Migraine and Tension-Type Headache (2004) (0)
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts (2023) (0)
Changes to Levodopa Daily Dose in Parkinson’s Disease (PD) Patients with Dyskinesia While on GocovriTM (Amantadine) Extended Release Capsules: a Two-Year Phase 3 Open Label Study Analysis (P4.7-010) (2019) (0)
Sequential drug holiday in Parkinson's disease (1984) (0)
Completeness and Validation of Automated Reporting to the California Parkinson’s Disease Registry (1318) (2020) (0)
O.098 Epidemiology of Parkinson's disease and related disorders – studies in special populations (2009) (0)
Does Mediterranean Diet Modify Phenoconversion in Huntington's Disease (HD) ? (P07.211) (2013) (0)
Modified out patient drug holiday in the management of parkinsonism (1981) (0)
Elevated Body Aluminum Stores Correlate with Cognitive and Motor Dysfunction in Chronic Dialysis (1987) (0)
Baseline Characteristics of Participants of the SPARK Trial, a Phase 2 Study of the anti-alpha-synuclein antibody Cinpanemab (BIIB054) in Parkinson’s Disease (1579) (2020) (0)
Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia (2022) (0)
Excessive Daytime Sleepiness and Neuron Loss in the Locus Coeruleus: The Honolulu-Asia Aging Study (P07.128) (2012) (0)
Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study (2023) (0)
ENVIRONMENTAL PERSPECTIVES ENVIRONMENTAL PERSPECTIVES (2008) (0)
RE-KINECT: A Prospective Real-World Dyskinesia Screening Study and Registry in Patients Taking Antipsychotic Agents: Patient Demographics (P4.083) (2018) (0)
Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease (2022) (0)
Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease (2020) (0)
Alzheimer’s Disease and Vascular Dementia (2004) (0)
The Impact of the COVID‐19 Pandemic on Care Partners of People with Parkinson's Disease (2023) (0)
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism (2021) (0)
Electrocardiographic changes predate Parkinson’s disease onset (2020) (0)
Loss of nLC neurons (1983) (0)
Prognosis of Neurologic Diseases (2004) (0)
Letters to the editor (0)
Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003) (2017) (0)
Genetic Epidemiology of Neurologic Disease (2004) (0)
Twenty second annual symposium on etiology, pathogenesis, and treatment of Parkinson's disease and other movement disorders (2008) (0)
Alpha‐synuclein: One key opens many locks (2013) (0)
Longitudinal Characterization of the Clinical and DAT Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort (S10.005) (2019) (0)
Clinical and Genetic Characteristics of Participants with Juvenile PD: The CORE-PD Study (IN10-2.001) (2012) (0)
Association of Slow Reaction Time with Future Risk of Parkinson's Disease in the Honolulu-Asia Aging Study (P03.063) (2013) (0)
Therapeutic Advances in Movement Disorders (2020) (0)
Regional North American Annual Meeting of the World Federation of Neurology – Research Group on Neuroepidemiology (2004) (0)
Reply (1987) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Caroline M. Tanner?

Caroline M. Tanner is affiliated with the following schools: